IFNB1 and neoplasm: In eligible patients, targeting dormant cells by combining molecules that trigger anti-tumor immunity, like IFN-β agonists or repressors of TGF-β1 signaling, with immune checkpoint inhibition might represent a successful strategy to control and eventually eradicate dormant cell niches.